Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 18Cisplatin 12Oxaliplatin 7pembrolizumab 6Nivolumab 6Capecitabine 4trametinib 3Fluorouracil 3Bevacizumab 3tremelimumab 2lenvatinib 2durvalumab 2derazantinib 2atezolizumab 2Trastuzumab 2Ramucirumab 2Radiofrequency Ablation 2Panitumumab 2Leucovorin 2Cryosurgery 2zanidatamab 1vandetanib 1tucatinib 1tocilizumab 1telotristat ethyl 1sargramostim 1rucaparib 1regorafenib 1pertuzumab 1milademetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Biliary Tract Neoplasms × adagrasib × Clear all
NCT06024174 2025-07-22

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Terminated
5 enrolled 9 charts
GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡